Fig. 2.
Fig. 2. Cell cycle. / (A) Effects of rituximab and dexamethasone on cell cycle. Statistically significant G1 arrest is observed in all 9 B-NHL cell lines following treatment with combined dexamethasone (10 μM) and rituximab (5 μg/mL) for 72 hours when compared with control. This figure demonstrates that the percentage of cells in G1 phase following rituximab and dexamethasone treatment is supra-additive in 4 B-NHL cell lines. Error bars represent SD of the mean in one experiment. The asterisk represents significantP values compared with the control (*P < .05; **P < .01; ***P < .001). (B) Rituximab and dexamethasone induced cell cycle arrest in DHL-4 cells. DNA content is demonstrated by propidium iodide staining following permeabilization of cells after treatment with control (Bi), rituximab alone (5 μg/mL) (Bii); dexamethasone alone (10 μM) (Biii); and rituximab (5 μg/mL) and dexamethasone (10 μM) (Biv). The mean percentage of cells in G1 phase from 3 experiments in the 4 treatment groups are 41% (Bi); 45% (Bii); 61% (Biii), P = .01; and 88%, P = .0004 (Biv). P values are 2 sided, comparing the treatment group to the control for 3 samples, obtained from the Student t test of independent samples. This is representative of at least 2 experiments.

Cell cycle.

(A) Effects of rituximab and dexamethasone on cell cycle. Statistically significant G1 arrest is observed in all 9 B-NHL cell lines following treatment with combined dexamethasone (10 μM) and rituximab (5 μg/mL) for 72 hours when compared with control. This figure demonstrates that the percentage of cells in G1 phase following rituximab and dexamethasone treatment is supra-additive in 4 B-NHL cell lines. Error bars represent SD of the mean in one experiment. The asterisk represents significantP values compared with the control (*P < .05; **P < .01; ***P < .001). (B) Rituximab and dexamethasone induced cell cycle arrest in DHL-4 cells. DNA content is demonstrated by propidium iodide staining following permeabilization of cells after treatment with control (Bi), rituximab alone (5 μg/mL) (Bii); dexamethasone alone (10 μM) (Biii); and rituximab (5 μg/mL) and dexamethasone (10 μM) (Biv). The mean percentage of cells in G1 phase from 3 experiments in the 4 treatment groups are 41% (Bi); 45% (Bii); 61% (Biii), P = .01; and 88%, P = .0004 (Biv). P values are 2 sided, comparing the treatment group to the control for 3 samples, obtained from the Student t test of independent samples. This is representative of at least 2 experiments.

Close Modal

or Create an Account

Close Modal
Close Modal